Chemomab Therapeutics Ltd. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Chemomab Therapeutics Ltd. (CMMB) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.19% for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-03-23
- Chemomab Therapeutics Ltd. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.14%, a 152.44% increase from fiscal 2021.
- Chemomab Therapeutics Ltd. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 1.64%, a 264.44% increase from fiscal 2020.
- Chemomab Therapeutics Ltd. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2020 was 0.45%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|
| 2025-12-31 | 4.19% 20-F · filed 2026-03-23 |
| 2024-12-31 | 4.50% 20-F · filed 2025-04-04 |
| 2023-12-31 | 4.43% 20-F · filed 2024-03-28 |
| 2022-12-31 | 4.14% 10-K · filed 2023-03-20 |
| 2021-12-31 | 1.64% 10-K · filed 2022-03-30 |
| 2020-12-31 | 0.45% 10-K · filed 2021-03-09 |